Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

Gene Therapy

Volumn 5, Issue 1, 1998, Pages 121-130

  Andreansky, S ^a   He, B ^b   Van Cott, J ^a   McGhee, J ^a   Markert, J M ^a   Gillespie, G Y ^a   Roizman, B ^b   Whitley, R J ^a,c  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c CHILDREN S HOSPITAL   (United States)

Author keywords

Glioma; Herpes simplex virus; Inflammatory cells; Interleukin 10; Interleukin 4; Intracerebral

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER SURVIVAL; CONTROLLED STUDY; EXPRESSION VECTOR; GENE THERAPY; GLIOMA; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS RECOMBINANT;

ANIMALIA; HERPES; MURINAE; SIMPLEXVIRUS;

EID: 0031963349     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300550     Document Type: Article

References (45)

1. Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993; 32: 597-603.
2. Chambers R et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 1995; 92: 1411-1415.
3. Andreansky S et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors Proc Natl Acad Sci USA 1996; 93: 11313-11318.
4. Roszman T, Elliott L, Brooks W. Modulation of T cell function by gliomas. Immunol Today 1991; 12: 370-374.
5. Tada M et al. Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor alpha for the treatment of malignant gliomas. Cancer Immunol Immunother 1993; 36: 251-239
6. Couldwell WT, Dore-Duffy P, Apuzzo ML, Antel JP. Malignant glioma modulation of immune function relative contribution of different soluble factors. J Neuroimmunol 1991; 33: 89-96.
7. Caruso M et al. Adenovirus-mediated interleukin 12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996; 93: 11302-11306.
8. Douvdevani A et al. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. Int J Cancer 1992; 51: 822-830.
9. Fearon ER et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
10. Tepper RI, Mulé JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5: 153-164.
11. Golumbek PT et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713-716
12. Mulé JJ, Custer MC, Travis WD, Rosenberg SA. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 1992; 148: 2622-2629.
13. Porgador A et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992; 52: 3679-3686.
14. + T cell-dependent tumor rejection. J Exp Med 1991; 174: 1291-1298.
15. Aoki T et al. Expression of murine interleukin 7 in a murine ghoma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 1992; 89: 3850-3854.
16. Porgador A et al. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes. J Immunother 1993; 14: 191-201.
17. Restifo NP et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
18. Blankenstein T et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991; 173: 1047-1052.
19. Asher AL et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors J Immunol 1991; 146: 3227-3234.
20. Allione A et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54: 6022-6026.
21. Dranoff G, Mulligan RC. Activities of granulocyte-macrophage colony-stimulating factor revealed by gene transfer and gene knockout studies. Stem Cells (Dayt) 1994; 12 (Suppl. 1): 173-182.
22. Kruger-Krasagakes S, Krasagakis K, Garbe C, Diamantstein T. Production of cytokines by human melanoma cells and melanocytes. Recent Results Cancer Res 1995; 139: 155-168.
23. Richter G et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 1993; 53: 4134-4137.
24. Cheng L, Ziegelhoeffer PR, Yang N-S. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993; 90: 4455-4459.
25. Yu JS et al. Treatment of glioma by engineered interleukin-4 secreting cells. Cancer Res 1993; 53: 3125-3128.
26. Ram Z et al. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J Neurosurg 1994; 80: 535-540.
27. Tjuvajev J et al. RG-2 ghoma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res 1995; 55: 1902-1910.
28. Wei MX et al. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum Gene Ther 1995; 6: 437-443.
29. 134.5, a gene nonessential for growth in cell culture. Science 1990; 252: 1262-1266.
30. - mutant of herpes simplex virus 1. J Virol 1997; 71: 5560-5569.
31. 134.5 gene of herpes simplex virus. J Virol 1994; 68: 8304-8311.
32. Moore KW et al. Interleukin-10. In: Paul WE, Fathmann CG, Metzger H (eds). Annual Reviews in Immunology (Volume 11). Annual Reviews: Palo Alto, 1993, pp 165-190.
33. Blume MR, Wilson CB, Vasquez D. Immune response to a transplantable intracerebral glioma in rats. In: Sane K, Ishi S, LeVay D (eds). Recent Progress in Neurologic Surgery. Excerpta: Amsterdam, 1974, pp 129-132.
34. Tapscott SJ et al. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA 1994; 91: 8185-8189.
35. Barba D, Hardin J, Sadelain M, Gage TH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-4352.
36. Boviatsis EJ et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994; 54: 5745-5751.
37. Post LE, Roizman B. A generalized technique for deletion of specific genes in large genomes: a gene 22 of herpes simplex virus 1 is not essential for growth. Cell 1981; 25: 227-232.
38. Jenkins FJ, Roizman B. Herpes simplex virus recombinants with non-inverting genomes frozen in different isomeric arrangements are capable of independent replication. J Virol 1986; 59: 494-499.
39. Ausman JI, Shapiro WR, Rall DP. Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 1970; 30: 2394-2400.
40. Seligman AM, Shear MJ. Studies in carcinogenesis. VIII. Experimental production of brain tumors in mice with methylchol-anthrene. Am J Cancer 1939; 37: 364-395.
41. Wiranowska M et al. Evaluation of blood-brain barrier permeability and the effect of interferon in mouse glioma model. J Neurooncol 1992; 14: 225-236.
42. Roizman B, Jenkins FJ. Generic engineering of novel genomes of large DNA viruses. Science 1985; 129: 1208-1218.
43. Lagunoff M, Roizman B. The regulation of synthesis and properties of the protein product of open reading frame P of the herpes simplex virus 1 genome. J Virol 1995; 69: 3615-3623.
44. Shin M-F, Arsenakis M, Tiollais P, Roizman B. Expression of hepatitis B virus S gene by herpes simplex virus 1 vectors carrying α and β regulated gene chimeras. Proc Natl Acad Sci USA 1984; 81: 5867-5870.
45. VanCott JL et al. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages and derived cytokines following oral immunization with live recombinant Salmonella. J Immunol 1996; 156: 1504-1514.